AVNC Advancis Pharmaceutical (MM)

Conference Call and Webcast to Follow GERMANTOWN, Md., Oct. 26 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical Corporation (NASDAQ:AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced it will release results for the quarter ended September 30, 2006, on Wednesday, November 1, 2006, before the market opens. A full text copy of the release will be disseminated at that time. Edward M. Rudnic, Ph.D., president and chief executive officer, will host a conference call to discuss the results and other corporate developments at 10:30 AM ET on Wednesday, November 1, 2006. Also participating on the call will be Robert C. Low, vice president, finance and CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:30 AM start time and ask for the Advancis Pharmaceutical conference call hosted by Dr. Rudnic. The teleconference dial-in numbers are as follows: Domestic callers 1-800-813-8504 International callers 1-706-643-7752 The conference call will be broadcast simultaneously and archived on the Company's web site, http://www.advancispharm.com/. Investors should go to the web site at least 15 minutes early to register, download, and install any necessary audio software. A replay of the call will be available on Wednesday, November 1, 2006, beginning at 12:30 PM ET and will be accessible until Wednesday, November 8, 2006, at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 9742528. About Advancis Pharmaceutical: Advancis Pharmaceutical Corporation (NASDAQ:AVNC) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently than those under standard treatment regimens. Based on this finding, Advancis has developed a proprietary, once-a-day pulsatile delivery technology called PULSYSTM. By examining the resistance patterns of bacteria and applying its delivery technologies, Advancis has the potential to redefine infectious disease therapy and significantly improve drug efficacy, shorten length of therapy, and reduce drug resistance versus currently available antibacterial products. For more on Advancis, please visit http://www.advancispharm.com/. DATASOURCE: Advancis Pharmaceutical Corporation CONTACT: Bob Bannon, Vice President, Investor Relations & Corporate Communications of Advancis Pharmaceutical Corp., +1-301-944-6710, Web site: http://www.advancispharm.com/

Copyright